Tdap vaccination in pregnancy
- PMID: 34860689
- PMCID: PMC8248450
- DOI: 10.1503/cmaj.202420
Tdap vaccination in pregnancy
Conflict of interest statement
Competing interests: Scott Halperin reports grants from GSK and Sanofi Pasteur related to research on pertussis-containing vaccines, as well as occasionally serving on advisory boards. He also reports payment for expert testimony by the province of Ontario regarding vaccine-associated adverse events. Scott Halperin is a member of a consortium that holds a patent for a novel adjuvant related to pertussis vaccines. He has also served on a clinical trial’s Data Safety Monitoring Board for pertussis vaccines in pregnancy. No other competing interests were declared.
References
-
- Update on immunization in pregnancy with Tdap vaccine: Update on immunization in pregnancy with tetanus toxoid, reduced diphtheria toxoid and reduced acellular pertussis (Tdap) vaccine. Public Health Agency of Canada; 2018, modified 2019 Oct. 9. Available: www.canada.ca/en/public-health/services/publications/healthy-living/upda... (accessed 2021 Mar. 5). - PMC - PubMed
-
- Abu Raya B, Edwards KM, Scheifele DW, et al. . Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infect Dis 2017;17:e209–22. - PubMed
-
- Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. ACOG Committee Opinion 718. Washington (DC): American College of Obstetricians and Gynecologists (ACOG). 2017. Available: www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/... (accessed 2021 Mar. 5).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical